Radicle Calm RDH: A Study Assessing the Impact of Health and Wellness Products on Feelings of Anxiety and Related Health Outcomes
NCT07219628 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 500
Last updated 2026-01-14
Summary
A randomized, double-blind, placebo-controlled direct-to-consumer study assessing the impact of health and wellness products on feelings of anxiety and related health outcomes.
Conditions
Interventions
- DIETARY_SUPPLEMENT
-
Calm Product Placebo Control
Participants will use their Calm Product Placebo Control as directed for a period of 6 weeks.
- DIETARY_SUPPLEMENT
-
Calm Active Product 1
Participants will use their Calm Active Product 1 as directed for a period of 6 weeks.
Sponsors & Collaborators
-
Radicle Science
lead INDUSTRY
Principal Investigators
-
Susan Hewlings · Radicle Science
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 21 Years
- Max Age
- 105 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-09-23
- Primary Completion
- 2025-12-14
- Completion
- 2025-12-14
Countries
- United States
Study Locations
More Related Trials
-
Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study
NCT03549819 ·Status: UNKNOWN ·Phase: PHASE3
-
Smartphones Aggravating Anxiety Symptoms
NCT06361342 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Efficacy and Safety of Inhaled NC-107 As Compared to Placebo After 4 Weeks of Treatment in Patients with Anxiety
NCT06656806 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder
NCT00106860 ·Status: COMPLETED ·Phase: PHASE3
-
Cannabidiol for Anxiety
NCT04267679 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects
NCT04592536 ·Status: COMPLETED ·Phase: PHASE1
-
Internet-delivered CBT for Anxiety Related to Asthma
NCT04230369 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Phospholipids as Nutritional Support for Reduction of Anxiety
NCT05837832 ·Status: UNKNOWN ·Phase: NA
-
Primary Care Intervention Strategy for Anxiety Disorders
NCT00347269 ·Status: COMPLETED ·Phase: PHASE4
-
Smartphone-Based Exposure Treatment for Dental Anxiety
NCT03461016 ·Status: COMPLETED ·Phase: NA
-
Cannabidiol Effects on Fear Extinction in Social Phobia
NCT06123702 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Evaluate the Beneficial Effects of an Oral Nutritional Supplement Based on Leonurus Cardiaca for the Improvement of Mood and Anxiety
NCT06954038 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder
NCT07123467 ·Status: RECRUITING ·Phase: PHASE3
-
Therapeutic Effect of an Herbal Medicine on Anxiety
NCT01178632 ·Status: UNKNOWN ·Phase: PHASE3
-
Experimental Medication For the Treatment of Generalized Anxiety Disorder
NCT00097708 ·Status: COMPLETED ·Phase: PHASE3
-
Cannabidiol as a Treatment for Social Anxiety Disorder (R61)
NCT05571592 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)
NCT05429788 ·Status: WITHDRAWN ·Phase: PHASE1
-
Xenon Inhalation for Treatment of Posttraumatic Stress Disorder
NCT03635827 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
NCT00236015 ·Status: COMPLETED ·Phase: PHASE3
-
Disentangling Anxiety Sensitivity and Anxiety-induced Physiological Stress Response
NCT02372110 ·Status: COMPLETED ·Phase: PHASE4
-
A Lifestyle Intervention to Reduce Cardiometabolic Risk Factors in Individuals With Obsessive-compulsive Disorder
NCT07206212 ·Status: RECRUITING ·Phase: NA
-
Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders
NCT02266446 ·Status: COMPLETED ·Phase: NA
-
Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder
NCT02066792 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study
NCT04569760 ·Status: WITHDRAWN ·Phase: PHASE3
-
Duloxetine vs Placebo in the Treatment of General Anxiety
NCT00475969 ·Status: COMPLETED ·Phase: PHASE3